163 related articles for article (PubMed ID: 1535212)
1. Reducing the cardiotoxicity of the anthracyclines.
Carlson RW
Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212
[TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity of anthracyclines].
Ferrière M; Donadio D; Ramirez R
Arch Mal Coeur Vaiss; 1993 Feb; 86 Spec No 2():53-8. PubMed ID: 8215791
[TBL] [Abstract][Full Text] [Related]
3. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
Mortensen SA; Aabo K; Jonsson T; Baandrup U
Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
[TBL] [Abstract][Full Text] [Related]
4. Detection of anthracycline-induced cardiotoxicity.
Meinardi MT; van der Graaf WT; van Veldhuisen DJ; Gietema JA; de Vries EG; Sleijfer DT
Cancer Treat Rev; 1999 Aug; 25(4):237-47. PubMed ID: 10448132
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
[TBL] [Abstract][Full Text] [Related]
6. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
7. [Cardiotoxicity of anthracyclines].
Laurent S; Colbert N; Izrael V; Motte G
Ann Med Interne (Paris); 1984; 135(6):464-72. PubMed ID: 6391323
[TBL] [Abstract][Full Text] [Related]
8. A historical perspective of anthracycline cardiotoxicity.
Ewer MS; Von Hoff DD; Benjamin RS
Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
[TBL] [Abstract][Full Text] [Related]
9. [Anthracyclines and the heart].
Mazzarello GP; Morra L
Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
12. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
13. [Cardiotoxicity of anthracycline].
Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
[TBL] [Abstract][Full Text] [Related]
14. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
Orditura M; De Vita F; Ciaramella F; Catalano G
Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
16. Monitoring for anthracycline cardiotoxicity.
Lipshultz SE; Sanders SP; Goorin AM; Krischer JP; Sallan SE; Colan SD
Pediatrics; 1994 Mar; 93(3):433-7. PubMed ID: 7818624
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-induced cardiomyopathy.
Keefe DL
Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
19. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
20. [Cardiac toxicity in cancer therapy].
Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
